mRNA Covid-19 vaccines could 'turbo-charge' cancer treatments

6 months ago

mRNA-based COVID-19 vaccines may enhance immunotherapy outcomes for cancer patients.
Patients receiving mRNA vaccines within 100 days of immunotherapy had higher survival rates.
Study involved over 1,000 advanced lung or skin cancer patients.
Three-year survival rate for lung cancer patients was 55.7% vs. 30.8% in unvaccinated.
mRNA vaccines may stimulate a general immune response, aiding cancer treatment.
Potential for mRNA technology to revolutionize oncologic care and create universal cancer vaccines.
Researchers planning late-stage clinical trials to validate findings.
Caution advised as results may be coincidental; healthier patients might skew outcomes.

Hasty Briefsbeta